Comparative Risk of Serious Infection With Vedolizumab vs Anti–Tumor Necrosis Factors in Inflammatory Bowel Disease
1Department of Gastroenterology, First Affiliated Hospital, China Medical University, Shenyang, Liaoning, China. Correspondence: Cong Dai, MD, PhD. E-mail: [email protected].
Authors
- Cong Dai (ORCID: https://orcid.org/0000-0003-1317-183X)
- Yühong Huang (ORCID: https://orcid.org/0000-0001-7562-2427)
- Min Jiang (ORCID: https://orcid.org/0000-0001-5125-1895)
Institutions
- First Hospital of China Medical University (CN)
- China Medical University (CN)
Publication Details
- Journal
- The American Journal of Gastroenterology
- Published
- 2024-08-19
- DOI
- https://doi.org/10.14309/ajg.0000000000002995
- Citations
- 1
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.55